SAN
DIEGO, Sept. 5, 2023 /PRNewswire/ -- Cardiff
Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology
company leveraging PLK1 inhibition, a well-validated oncology drug
target, to develop novel therapies across a range of cancers, today
announced that company management will present at the Baird Global
Healthcare Conference on September 12,
2023 and the H.C. Wainwright 25th Annual Global
Investment Conference on September 13,
2023.
Details of the presentations can be found below.
Baird Global Healthcare Conference [only available to live
participants]
Location: InterContinental New York
Barclay
Presenter: Mark Erlander, CEO
Format: Fireside Chat
Date: 09/12/2023
Time: 9:05 AM ET
H.C. Wainwright 25th Annual Global Investment
Conference
Location: Lotte New York Palace Hotel
Presenter: Mark Erlander, CEO
Format: Company Presentation
Date: 09/13/2023
Time: 11:30 AM ET
Interested parties can register for and access the live webcast
for H.C. Wainwright by visiting the "Events" section of the Cardiff
Oncology website. The webcast replay will be available after the
conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company
leveraging PLK1 inhibition, a well-validated oncology drug target,
to develop novel therapies across a range of cancers. The Company's
lead asset is onvansertib, a PLK1 inhibitor being evaluated in
combination with standard-of-care (SoC) therapeutics in clinical
programs targeting indications such as RAS-mutated metastatic
colorectal cancer (mCRC) and metastatic pancreatic ductal
adenocarcinoma (mPDAC), as well as in investigator-initiated trials
in triple negative breast cancer (TNBC) and small cell lung cancer
(SCLC). These programs and the Company's broader development
strategy are designed to target tumor vulnerabilities in order to
overcome treatment resistance and deliver superior clinical benefit
compared to the SoC alone. For more information, please
visit https://www.cardiffoncology.com.
Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com
Investor Contact:
Kiki
Patel, PharmD
Gilmartin Group
332-895-3225
Kiki@gilmartinir.com
Media Contact:
Richa
Kumari
Taft Communications
551 344-5592
richa@taftcommunications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-upcoming-investor-conferences-in-september-301916201.html
SOURCE Cardiff Oncology, Inc.